Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.

MLA

Poveda, A., et al. “Phase II Randomized Study of PM01183 versus Topotecan in Patients with Platinum-Resistant/Refractory Advanced Ovarian Cancer.” Annals of Oncology, vol. 28, no. 6, June 2017, pp. 1280–87. EBSCOhost, https://doi.org/10.1093/annonc/mdx111.

APA

Poveda, A., del Campo, J. M., Ray-Coquard, I., Alexandre, J., Provansal, M., Guerra Alía, E. M., Casado, A., Gonzalez-Martin, A., Fernández, C., Rodriguez, I., Soto, A., Kahatt, C., Fernández Teruel, C., Galmarini, C. M., Pérez de la Haza, A., Bohan, P., & Berton-Rigaud, D. (2017). Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer. Annals of Oncology, 28(6), 1280–1287. https://doi.org/10.1093/annonc/mdx111

Chicago

Poveda, A., J. M. del Campo, I. Ray-Coquard, J. Alexandre, M. Provansal, E. M. Guerra Alía, A. Casado, et al. 2017. “Phase II Randomized Study of PM01183 versus Topotecan in Patients with Platinum-Resistant/Refractory Advanced Ovarian Cancer.” Annals of Oncology 28 (6): 1280–87. doi:10.1093/annonc/mdx111.